Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation

INTRODUCTION: Genomic aberrations involving ALK, ROS1 and MET can be driver oncogenes in lung adenocarcinomas. Identification of tyrosine kinase inhibitors (TKIs) with activity against these tumors and of preclinical systems to model response are warranted. METHODS: We analyzed cases with lung adeno...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lung Cancer
Main Authors: Jorge, Susan E., Schulman, Sol, Freed, Jason A., VanderLaan, Paul A., Rangachari, Deepa, Kobayashi, Susumu S., Huberman, Mark S., Costa, Daniel B.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4724060/
https://ncbi.nlm.nih.gov/pubmed/26791794
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.lungcan.2015.10.028
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados